Lead Product(s) : CVHNLC,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CureVac Receives FDA IND for mRNA Immunotherapy in Squamous NSCLC
Details : CVHNLC is CureVac's investigational mRNA-based precision immunotherapy consisting of two different mRNA constructs encoding eight tumor-associated antigens with prevalence across sqNSCLC patients.
Product Name : CVHNLC
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 07, 2025
Lead Product(s) : CVHNLC,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ariceum Files for UK CTA for Iodine-123 PARP Inhibitor in Glioblastoma
Details : ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.
Product Name : ATT001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2024
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MDG1015
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Medigene Gets FDA Clearance for MDG1015, a TCR-T Therapy for Solid Tumors
Details : MDG1015 is a first-in-class, TCR-T therapy targeting NY-ESO-1/ LAGE-1a. It is being developed for gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.
Product Name : MDG1015
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : MDG1015
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ariceum Granted UK Authorisation for Phase I Study of Iodine-123 in Glioblastoma
Details : ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.
Product Name : ATT001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : ATT001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBE-101
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Cell BioEngines
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Miltenyi will develop and manufacture Cell BioEngines' expanded hematopoietic stem cell transplantation (HSCT) product, CBE-101, for clinical use in hematology-oncology.
Product Name : CBE-101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 29, 2023
Lead Product(s) : CBE-101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Cell BioEngines
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SY-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Syena
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Syena will support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy, SY-001, targeting the tumor-associated neoantigen, PRAME.
Product Name : SY-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : SY-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Syena
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : VIP943
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vincerx Pharma Announces FDA Clearance of IND for VIP943
Details : VIP943 is a novel ADC developed using Vincerx’s next-generation ADC technology designed to bind with CD123 and is being investigated in acute myeloid leukemia.
Product Name : VIP943
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 22, 2023
Lead Product(s) : VIP943
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acimtamig,AB-101
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Artiva Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AFM13 is a first-in-class innate cell engager (ICE®) that uniquely leverags the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages to destroy CD30-positive hematologic tumors.
Product Name : AFM13
Product Type : Antibody
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Acimtamig,AB-101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Artiva Biotherapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VIP236
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VIP236 is a small molecule drug conjugate with an optimized camptothecin payload having a significant activity in patient-derived and metastatic cancer models. It is being developed for treating multiple solid tumors.
Product Name : VIP236
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : VIP236
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AFM28
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AFM28, a tetravalent bispecific CD123- and CD16A-binding ICE® developed on Affimed’s ROCK® platform, is designed to bring a new immunotherapeutic approach to patients with CD123-positive myeloid malignancies, including AML and MDS.
Product Name : AFM28
Product Type : Antibody
Upfront Cash : Inapplicable
December 21, 2022
Lead Product(s) : AFM28
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable